The North America enzyme replacement therapy market reached USD 4.82 billion in 2026. The rising prevalence of rare diseases and growing research and development activities drive the market, encouraging stakeholders to develop innovative enzyme replacement therapy (ERT). These trends were analyzed by Deepa Pandey, Senior Research Analyst, to curate this report. Her report benefits drug manufacturers, research firms, delivery technology developers, and specialized service providers.